Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.35 |
| ▸ | ESR1 | P03372 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.31 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.31 |
| ▸ | GRIA4 | P48058 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20573106 | 0.98 | ALDH1A1 (0.35) | SLC6A2SLC6A3ESR1PGRCHRM2 | |
| SCHEMBL29138432 | 0.79 | SLC6A2 (0.38) | SLC6A2SLC6A3ESR1PGRCHRM2 | |
| SCHEMBL13881363 | 0.77 | GRIK1 (0.35) | SLC6A2SLC6A3ESR1PGRCHRM2 | |
| SCHEMBL6047678 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL29138431 | 0.76 | ALDH1A1 (0.39) | SLC6A2SLC6A3ESR1PGRCHRM2 | |
| SCHEMBL20262411 | 0.76 | KMT2A (0.49) | SLC6A2SLC6A3ESR1PGRCHRM2 | |
| SCHEMBL3179017 | 0.76 | MAPT (0.38) | KMT2AALDH1A1GRIK1MAPTHPGD | |
| SCHEMBL20262491 | 0.73 | ADRA1A (0.47) | SLC6A2SLC6A3ESR1PGRCHRM2 | |
| SCHEMBL3200633 | 0.73 | MAPT (0.39) | KMT2AALDH1A1MAPTHPGDLMNA | |
| SCHEMBL6551852 | 0.73 | GRIK1 (0.40) | SLC6A2SLC6A3ESR1PGRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN S | 2005-11-10 | — | — | US | disclosed |
| EP-1311470-B1 | UNSATURATED ESTERS AND THEIR USE IN FRAGRANCE AND FLAVOUR COMPOSITIONS | GIVAUDAN SA (CH) | 2004-11-03 | — | — | EP | disclosed |
| US-20040023839-A1 | Unsaturated esters and their use in fragance and flavour compositions | GIVAUDAN SA (CH) | 2004-02-05 | — | — | US | disclosed |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2003-06-26 | — | — | US | disclosed |
| EP-1311470-A1 | UNSATURATED ESTERS AND THEIR USE IN FRAGRANCE AND FLAVOUR COMPOSITIONS | Givaudan SA (CH) | 2003-05-21 | — | — | EP | disclosed |
| US-6489352-B2 | ANTIEPILEPTIC AGENTS; NERVOUS SYSTEM DISORDERS | WARNER-LAMBERT COMPANY | 2002-12-03 | — | — | US | disclosed |
| WO-2002016307-A1 | UNSATURATED ESTERS AND THEIR USE IN FRAGRANCE AND FLAVOUR COMPOSITIONS | GIVAUDAN SA (CH) | 2002-02-28 | — | — | WO | disclosed |
| EP-1182190-A1 | Unsaturated esters | Givaudan SA (CH) | 2002-02-27 | — | — | EP | disclosed |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | BRYANS JUSTIN STEPHEN (GB) | 2002-02-14 | — | — | US | disclosed |
| US-6316638-B1 | FOR THERAPY OF EPILEPSY, FAINTNESS ATTACKS, HYPOKINESIA, CRANIAL DISORDERS, NEURODEGENERATIVE DISORDERS, DEPRESSION, ANXIETY, PANIC, PAIN, AND NEUROPATHOLOGICAL DISORDERS | WARNER-LAMBERT COMPANY | 2001-11-13 | — | — | US | disclosed |
| EP-1082306-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 2001-03-14 | — | — | EP | disclosed |
| WO-1999061424-A1 | CONFORMATIONALLY CONSTRAINED AMINO ACID COMPOUNDS HAVING AFFINITY FOR THE ALPHA2DELTA SUBUNIT OF A CALCIUM CHANNEL | WARNER-LAMBERT COMPANY (US) | 1999-12-02 | — | — | WO | disclosed |
| EP-0358092-B1 | 2-AZA-4-(ALKOXYCARBONYL)SPIRO-(4,5)DECAN-3-ONE | LONZA A.G. (CH) | 1991-12-11 | — | — | EP | disclosed |
| US-4958044-A | 2-aza-4-(alkoxycarbonyl)spiro[4,5]-decan-3-one | LONZA LTD. (CH) | 1990-09-18 | — | — | US | disclosed |
| US-4956473-A | ANTICONVULSANTS | LONZA LTD. (CH) | 1990-09-11 | — | — | US | disclosed |
| EP-0358092-A1 | 2-Aza-4-(alkoxycarbonyl)spiro-(4,5)decan-3-one | LONZA A.G. (CH) | 1990-03-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050250800-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, GABRA6, GABRA2 | SLC6A2 331/4885SLC6A3 348/4885ESR1 4862/4885 |
| US-20020019540-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | SLC6A2 715/4885SLC6A3 747/4885ESR1 4856/4885 |
| US-20040023839-A1 | Unsaturated esters and their use in fragance and flavour compositions | ELOVL5, FFAR3, ELOVL1 | SLC6A2 4463/4885SLC6A3 4389/4885ESR1 176/4885 |
| US-20030119858-A1 | Conformationally constrained compounds as pharmaceutical agents | PYGB, SLC18A1, CDR2 | SLC6A2 715/4885SLC6A3 747/4885ESR1 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.